Comparative Pharmacology
Head-to-head clinical analysis: ACHROMYCIN versus RONDOMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACHROMYCIN versus RONDOMYCIN.
ACHROMYCIN vs RONDOMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
250-500 mg orally every 6 hours or 500 mg intravenously every 12 hours.
150 mg orally twice daily or 300 mg orally once daily.
None Documented
None Documented
6-12 hours; prolonged to 48-72 hours in severe renal impairment
Terminal elimination half-life is 6-8 hours in patients with normal renal function; may extend to 20-30 hours in severe renal impairment.
Renal (60-80% unchanged via glomerular filtration); biliary/fecal (10-20%)
Renal (40-50% unchanged), biliary/fecal (10-20% as metabolites and unchanged drug). Approximately 30% undergoes enterohepatic circulation.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic